Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

By Julie Trulson, Ph.D., Vice President and Head of CMC, Asher Biotherapeutics

Asher Biotherapeutics, a company developing a new generation of immunotherapies, needed a partner to help bring their creations to life. Their cis-targeted immunotherapies precisely activate the immune system's beneficial cells, unlike traditional therapies with broader effects. Asher sought a CDMO capable of handling everything from early-stage projects to full-scale commercial production for their most promising candidates. While the technical expertise and capacity of a large CDMO like Lonza were appealing, Asher worried a big company might not prioritize their pipeline or offer the flexibility they needed in developing and implementing their treatments.